Mapmygenome Lung cancer nicotine dependency test
May 31, 2014 – HYDERABAD, India — Hyderabad, India, May 31, 2014:
Mapmygenome India launched a new DNA-based Lung Cancer and Nicotine Dependence test on World No Tobacco Day, May 31, 2014. This test decodes DNA, finds specific changes in the code, and assesses the genetic risk for lung cancer and nicotine dependence. Priced at INR 15,000, this test is recommended to people who have a history of smoking and exposure to environmental tobacco smoke.
Ms. Anu Acharya, CEO of Mapmygenome, said “Our genetics-based lung cancer and nicotine dependence test is the culmination of requests from several key members of the medical community. This is our way of saying No to tobacco and Yes to oxygen.”
The test uses single nucleotide polymorphism genotyping of proven markers associated with lung cancer in order to study inherited and acquired changes in DNA that contribute to the disease risk. The nicotine dependence markers allow users to understand their nicotine dependence pattern and formulate better smoking cessation plans.
Mapmygenome is India’s pioneering Genomics Company with a vision to provide “Better Health for Indians using
technology.” They offer personal genomics & diagnostic tests, disease detection kits, brain wellness solutions, and
They have a range of personal genomics tests that include Genomepatri™ personal genetic profile featuring
100+ conditions and traits; Cardiomap™ genetic test for heart disease, diabetes, and other associated lifestyle
conditions; Oncomap™ test for cancer; and Gynaecmap™ test for women. These tests assess not only genetic
risks for diseases, traits, and conditions, but also responses to several drugs prescribed for treatment. Counseling
services such as genetic counseling and nutrition counseling add value to the tests. Along with their partners in
diagnostics and healthcare, Mapmygenome paves way for customers to receive the best attention required to
mitigate the risk of diseases.
includes MyCalmBeat™ to reduce stress, to improve lung function, and to optimize heartbeat. Another innovative
product in this range is WebNeuro™ test to screen cognitive strengths and efficiency.
diagnostic tests for β-Thalassemia, Hepatitis B, Hepatitis C, and HIV. More kits and tests will be launched soon
Their team at Hyderabad comprises biotechnologists, statisticians, geneticists, bioinformaticians, medical writers,
and genetic counselors. Their advisory panel has expert scientists and doctors. In order to enhance this innovative
brand and to provide value-added services to customers, their highly skilled research team works on cutting-edge
technologies in various domains.
For more information, visit: Mapmygenome